Home
/
BioRestorative Therapies, Inc.
/
Financials
/
Quarterly
BioRestorative Therapies, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BioRestorative Therapies, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2024
Jun 30, 2024
$0
Aug 13, 2024
Q3
2019
Sep 30, 2019
$38.0K
Nov 13, 2019
Q2
2019
Jun 30, 2019
$31.0K
Aug 14, 2019
Q1
2019
Mar 31, 2019
$29.0K
May 15, 2019
Q3
2019
Sep 30, 2018
$26.0K
Nov 13, 2019
Q2
2019
Jun 30, 2018
$37.0K
Aug 14, 2019
Q1
2019
Mar 31, 2018
$19.0K
May 15, 2019
Q3
2018
Sep 30, 2017
$16.0K
Nov 13, 2018
Q2
2018
Jun 30, 2017
$20.0K
Aug 14, 2018
Q1
2018
Mar 31, 2017
$7.0K
May 15, 2018
Q3
2017
Sep 30, 2016
$5.0K
Nov 14, 2017
Q2
2017
Jun 30, 2016
$16.2K
Aug 14, 2017
Q1
2017
Mar 31, 2016
$9.1K
May 15, 2017
Q3
2016
Sep 30, 2015
$96.1K
Nov 14, 2016
Q2
2016
Jun 30, 2015
$148.8K
Aug 15, 2016
Q1
2016
Mar 31, 2015
$184.9K
May 13, 2016
Q3
2015
Sep 30, 2014
$159.9K
Nov 23, 2015
Q2
2015
Jun 30, 2014
$175.9K
Aug 14, 2015
Q1
2015
Mar 31, 2014
$375
May 15, 2015
Q3
2014
Sep 30, 2013
$125
Nov 13, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$11.8K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$303.3K
Aug 12, 2025
Q1
2025
Mar 31, 2025
$25.0K
May 14, 2025
Q3
2025
Sep 30, 2024
$233.6K
Nov 12, 2025
Q2
2025
Jun 30, 2024
$89.1K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$35.0K
May 14, 2025
Q3
2024
Sep 30, 2023
$30.7K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$64.5K
Aug 13, 2024
Q1
2024
Mar 31, 2023
$31.3K
Jun 11, 2024
Q3
2023
Sep 30, 2022
$29.0K
Nov 13, 2023
Q2
2023
Jun 30, 2022
$71.1K
Aug 11, 2023
Q1
2023
Mar 31, 2022
$16.0K
May 12, 2023
Q3
2022
Sep 30, 2021
$8.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$15.0K
Aug 15, 2022
Q1
2022
Mar 31, 2021
$18.0K
May 16, 2022
Q3
2021
Sep 30, 2020
$15.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$19.0K
Aug 16, 2021
Q1
2021
Mar 31, 2020
$26.0K
May 17, 2021
Q3
2020
Sep 30, 2019
$38.0K
Apr 12, 2021
Q2
2020
Jun 30, 2019
$31.0K
Apr 12, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.04M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($2.66M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($2.66M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($5.34M)
May 14, 2025
Q2
2025
Mar 31, 2025
($5.34M)
Aug 12, 2025
Q3
2025
Mar 31, 2025
($5.34M)
Nov 12, 2025
Q3
2025
Sep 30, 2024
($1.09M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($4.03M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($4.03M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($2.22M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($2.22M)
May 14, 2025
Q3
2025
Mar 31, 2024
($2.22M)
Nov 12, 2025
Q3
2024
Sep 30, 2023
$4.77M
Nov 12, 2024
Q2
2024
Jun 30, 2023
($5.71M)
Aug 13, 2024
Q3
2024
Jun 30, 2023
($5.71M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($7.17M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($7.17M)
Jun 11, 2024
Q3
2024
Mar 31, 2023
($7.17M)
Nov 12, 2024
Q3
2022
Sep 30, 2022
($4.66M)
Nov 14, 2022
Q3
2023
Jun 30, 2022
($4.68M)
Nov 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.71M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($3.31M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($4.81M)
May 14, 2025
Q3
2025
Sep 30, 2024
($2.29M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($2.47M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($4.11M)
May 14, 2025
Q3
2024
Sep 30, 2023
($3.10M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($3.12M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($5.78M)
Jun 11, 2024
Q3
2023
Sep 30, 2022
($4.61M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($4.63M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($5.05M)
May 12, 2023
Q3
2022
Sep 30, 2021
($3.69M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($3.56M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($15.05M)
May 16, 2022
Q3
2021
Sep 30, 2020
($610.3K)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($461.6K)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($819.0K)
May 17, 2021
Q3
2020
Sep 30, 2019
($1.82M)
Apr 12, 2021
Q2
2020
Jun 30, 2019
($2.13M)
Apr 12, 2021